Background/Objectives: Osteoarthritis, the principal indication for joint arthroplasty, has doubled in incidence since 1990. Advances in surgical techniques, combined with an ageing population, have driven a substantial rise in arthroplasty procedures, presenting numerous challenges for healthcare systems worldwide. This study analyses historical trends in joint arthroplasty, assesses the accuracy of prior projections, and forecasts future demand using data from international arthroplasty registries. The goal is to guide healthcare resource management and policymaking. Methods: A systematic registry search identified 15 nations’ joint arthroplasty registries, and 209 annual reports provided high-quality data on primary total hip (THA) and knee arthroplasties (TKA) over the past two decades. Future arthroplasty volumes were projected using a deterministic negative-exponential saturating growth model. Results: From 2010 to 2023, THA incidence rose by 130% to 210%, while TKA increased by 150% to 664% across the analysed national registries. Projections to 2050 indicate sustained growth: THA volumes are expected to rise by 121% to over 200% and TKA by at least 130% across all countries. Conclusions: The ongoing escalation in joint arthroplasty demand necessitates proactive healthcare planning. Without strategic investments in infrastructure, workforce capacity, and digital resources, national healthcare systems risk being overwhelmed by the projected growth in both primary and revision procedures in the coming decades.

Periodontitis is the irreversible destructive process of the periodontium and is the major cause of tooth loss in adults worldwide. Diagnosis of early-stage periodontal disease is crucial for improving outcomes, and to this end, the application of indicator biomarkers is gaining interest. One such method involves measuring the level of matrix metalloproteinase-8 (MMP-8). This systematic review and meta-analysis aims to evaluate the salivary MMP-8 level of periodontitis and gingivitis cases compared to healthy controls. We evaluated all studies that compared different laboratory techniques for measuring salivary MMP-8 levels in periodontitis and gingivitis patients, alongside healthy controls. The systematic search was performed on 10 October 2022 in three electronic databases. Pooled mean differences (MD) were calculated with 95 % confidence intervals (CIs) between the researched groups. In addition, the correlation coefficient results between MMP-8 values and other clinical parameters were narratively summarized. Based on 20 eligible studies (n = 1725), patients with periodontitis presented significantly higher MMP-8 levels (MD = 273.26 ng/ml, CI: 194.42; 352.10). Similarly, patients with gingivitis presented significantly higher salivary MMP-8 levels than healthy individuals (MD = 122.82 ng/ml, CI: 64.19; 181.45) based on the results of 10 eligible studies (n = 704). Additionally, we found higher MMP-8 levels in periodontitis compared to gingivitis (MD = 112.04 ng/ml, CI: 56.15; 167.92). The correlation results suggest that salivary MMP-8 is associated with different clinical periodontal parameters. Salivary MMP-8 level measurement may be a reliable method to distinguish between periodontal health and periodontal disease and also to distinguish between gingivitis and periodontitis. The measurement of salivary MMP-8 levels may have the potential to differentiate between periodontal health and disease reliably. Accordingly, it can be considered for integration into routine dental examinations as a quick and convenient method for the early detection and prevention of periodontitis, pending further validation.

Background: Ridge resorption following tooth extraction may be reduced by alveolar ridge preservation (ARP). Previous randomized clinical trials and systematic reviews have suggested that autogenous tooth bone graft (ATB) can be an effective alternative material for ARP. However, the results are heterogeneous. Therefore, our research aimed to evaluate the efficacy of ATB in ARP. Methods: A systematic search was conducted in Cochrane Library, Embase, MEDLINE and Scopus for studies published from inception to 31 November 2021. We searched searched for randomized, non-randomized controlled trials and case series reporting on ATB use for ARP. The primary outcome was the ridge width difference pre- and post-surgery, measured in millimetres (mm) measured on CBCT (cone beam computed tomography). The secondary outcomes were the histological results. We followed the PRISMA2020 recommendations for reporting our systematic review and meta-analysis. Results: The analysis included eight studies for the primary and six for the secondary outcomes. The meta-analysis revealed a positive ridge preservation effect with a pooled mean difference ridge width change of -0.72 mm. The pooled mean residual graft proportion was 11.61%, and the newly formed bone proportion was 40.23%. The pooled mean of newly formed bone proportion was higher in the group where ATB originated from both the root and crown of the tooth. Conclusions: ATB is an effective particulate graft material in ARP. Complete demineralization of the ATB tends to decrease the proportion of newly formed bone. ATB can be an attractive option for ARP. Trial registration: The study protocol was registered on PROSPERO (CRD42021287890).

Repeated positivity and reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) is a significant concern. Our study aimed to evaluate the clinical significance of repeatedly positive testing after coronavirus disease 2019 (COVID-19) recovery. We performed a systematic literature search following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. With available individual patient data reporting on repeatedly SARS-CoV-2 positive (RSP) patients, case reports, and case series were included in this analysis. We performed a descriptive analysis of baseline characteristics of repeatedly positive cases. We assessed the cases according to the length of their polymerase chain reaction (PCR) negative interval between the two episodes. Risk factors for the severity of second episodes were evaluated. Overall, we included 123 patients with repeated positivity from 56 publications, with a mean repeated positivity length of 47.8 ± 29.9 days. Younger patients were predominant in the delayed (>90 days) recurrent positive group. Furthermore, comparing patients with RSP intervals of below 60 and above 60 days, we found that a more severe disease course can be expected if the repeated positivity interval is shorter. Severe and critical disease courses might predict future repeatedly positive severe and critical COVID-19 episodes. In conclusion, our results show that the second episode of SARS-CoV-2 positivity is more severe if it happens within 60 days after the first positive PCR. On the other hand, the second episode’s severity correlates with the first.

Currently, there is no specific pharmaceutical agent for treating acute pancreatitis (AP). Somatostatin and its analogues have been used to prevent the autolysis of the pancreas in AP, however, their effectiveness has not been confirmed. This investigation aimed to examine the efficacy of ulinastatin, a protease inhibitor, combined with somatostatin analogues in the treatment of AP. We conducted a systematic database search in 4 databases to identify randomized controlled trials in which the efficacy of ulinastatin in combination with somatostatin analogue was compared to somatostatin analogue alone in patients with AP. Since the patient populations of analysed papers were slightly different, we used random effect models to pool odds ratios (OR) and mean differences (MD) and the corresponding 95% confidence intervals (CI). A total of 9 articles comprising 1037 patients were included in the meta-analysis. The combination therapy significantly reduced the complication rates for acute respiratory distress syndrome, acute kidney injury, and multiple organ dysfunction. Symptoms were relieved threefold with the combination therapy compared to somatostatin alone, and combination therapy significantly shortened the length of hospital stay. The decrease in mortality was not statistically significant.

This systematic review and meta-analysis evaluated the prognostic role of cell-free DNA (cfDNA) in pancreatic ductal adenocarcinoma (PDAC). Eligible studies reported differences in overall (OS) and progression-free survival (PFS) by cfDNA status. The random effect model yielded the pooled hazard ratios (HRs) and 95 % confidence intervals (CI). Detection of circulant-tumor DNA (ctDNA), KRAS mutations and other cfDNA alterations constitute detectable cfDNA biomarkers. Altogether, 38 studies (3,318 patients) were eligible. Progression-free and overall survival were decreased with detectable ctDNA (HR = 1.92, 95 %CI:(1.29,2.86); HR = 2.25, 95 %CI:(1.73,2.92)) and KRAS mutations (HR = 1.88, CI:1.22,2.92,); HR = 1.52, 95 %CI:(1.22,1.90)) respectively, across various stages. In unresectable cases, ctDNA (HR = 2.50, 95 %CI:(1.94,3.23)), but not KRAS mutations (HR = 1.16, 95 %CI:(0.46,2.94)) signaled risk for progression. Detectable cfDNA biomarkers correlated with worse prognosis in resectable cases and if detected during treatment. In conclusion, cfDNA biomarkers indicate accelerated progression and decreased survival in PDAC. Significance of KRAS mutations detection in unresectable cases is to be determined.